Lymphocyte Biomarkers of Clinical Responses to Adoptive Immunotherapy of Malignant Melanoma - Archive ouverte HAL Access content directly
Journal Articles Current Cancer Therapy Reviews Year : 2008

Lymphocyte Biomarkers of Clinical Responses to Adoptive Immunotherapy of Malignant Melanoma

(1) , (2) , (1, 3)
1
2
3

Abstract

During the last few years, adoptive cellular therapy (ACT)-the isolation of antigen-specific lymphocytes, their ex vivo expansion and activation, and subsequent autologous administration-has been tested for treatment of melanoma tumours. Initial ACT used melanoma-infiltrating lymphocytes (TIL) that often contain tumour reactive lym-phocytes, of diverse, mostly unknown, specificities [1, 2]. Recently, the identification of melanoma antigens [3] and the development of techniques for selection and expansion of epitope specific T cells has opened the way to the use of tumour antigen specific T cells, and importantly to immune follow up of ACT [4-9]. Despite these advances, several issues remain to address to achieve the major aims of ACT, as the rapid production of clinical grade T cells capable of eliciting a significant destruction of tumour tissue.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-02482037 , version 1 (17-02-2020)

Identifiers

  • HAL Id : inserm-02482037 , version 1

Cite

Nathalie Labarrière, Brigitte Dréno, Francine Jotereau. Lymphocyte Biomarkers of Clinical Responses to Adoptive Immunotherapy of Malignant Melanoma. Current Cancer Therapy Reviews, 2008, 4 (2), pp.125 - 129. ⟨inserm-02482037⟩
12 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More